Adam's Take - Page 2 of 6

Adam's Take

Gilead’s new CEO hasn’t shown up for work yet, leaving the biotech rudderless, investors anxious

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Rexahn, Omeros, and Cel-Sci

By Adam Feuerstein

Biotech

Aurinia’s flop in dry-eye trial brings an unexpected victory — and a shot at challenging Allergan

By Adam Feuerstein

Adam's Take

Lipocine fatty liver drug study results don’t hold up to scrutiny

By Adam Feuerstein

Adam's Take

Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher

By Adam Feuerstein

Adam's Take

It’s day one at JPM19. Here’s what we heard and learned

By Adam Feuerstein

Adam's Take

On the cusp of the ‘JPM,’ here’s a cheat sheet for what to watch in biotech in 2019

By Adam Feuerstein

Adam's Take

Leiden victorious in best biopharma CEO tally; Alles tops worst list

By Adam Feuerstein

Adam's Take

And now, your nominees for worst biopharma CEO of 2018. Let the voting begin!

By Adam Feuerstein

Adam's Take

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

By Adam Feuerstein

Adam's Take

Why Gilead’s new CEO is a solid choice to help the biotech grow again

By Adam Feuerstein

Adam's Take

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

By Adam Feuerstein

Adam's Take

Ziopharm shares are moving higher on a turnaround strategy, but is it for real? A closer look

By Adam Feuerstein

Adam's Take

If biotech stock values are down, why isn’t M&A picking up?

By Adam Feuerstein

Adam's Take

Biotech is looking woozy: ferocious selling and a sense of foreboding

By Adam Feuerstein

Adam's Take

Amarin, Vascepa, and mineral oil. There is more to consider with this fish-oil drug story

By Adam Feuerstein

Adam's Take

Skin cancer immunotherapy could have potential but don’t hang hopes on new data

By Adam Feuerstein

Adam's Take

Acadia Pharma conjures black magic to spin a failed depression drug trial

By Adam Feuerstein

Adam's Take

Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy

By Adam Feuerstein

Adam's Take

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

By Adam Feuerstein

Adam's Take

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

By Adam Feuerstein

Adam's Take

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

By Adam Feuerstein

Adam's Take

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

By Adam Feuerstein

Adam's Take

Ahead of Geron blowup, warning signs were visible for those willing to see them

By Adam Feuerstein

Adam's Take

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

By Adam Feuerstein

Adam’s Take

Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes

Taking the measure of small-cap biotech: Fennec Pharma, Actinium Pharma

What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease

Taking the measure of small-cap biotech: Bellus Health, OncoSec Medical

Gilead’s new CEO hasn’t shown up for work yet, leaving the biotech rudderless, investors anxious

Taking the measure of small-cap biotech: Rexahn, Omeros, and Cel-Sci

Aurinia’s flop in dry-eye trial brings an unexpected victory — and a shot at challenging Allergan

Lipocine fatty liver drug study results don’t hold up to scrutiny

Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher

It’s day one at JPM19. Here’s what we heard and learned

On the cusp of the ‘JPM,’ here’s a cheat sheet for what to watch in biotech in 2019

Leiden victorious in best biopharma CEO tally; Alles tops worst list

And now, your nominees for worst biopharma CEO of 2018. Let the voting begin!

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

Why Gilead’s new CEO is a solid choice to help the biotech grow again

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

Ziopharm shares are moving higher on a turnaround strategy, but is it for real? A closer look

If biotech stock values are down, why isn’t M&A picking up?

Biotech is looking woozy: ferocious selling and a sense of foreboding

Amarin, Vascepa, and mineral oil. There is more to consider with this fish-oil drug story

Skin cancer immunotherapy could have potential but don’t hang hopes on new data

Acadia Pharma conjures black magic to spin a failed depression drug trial

Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

Ahead of Geron blowup, warning signs were visible for those willing to see them

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback